Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 28, 2013, Pages 11517-11522

  Kocatürk, Begüm ^a   Van Den Berg, Yascha W ^a   Tieken, Chris ^a   Mieog, J Sven D ^a   De Kruijf, Esther M ^a   Engels, Charla C ^a   Van Der Ent, Martijn A ^a   Kuppen, Peter J ^a   Van De Velde, Cornelis J ^a   Ruf, Wolfram ^b   Reitsma, Pieter H ^a   Osanto, Susanne ^a   Liefers, Gerrit Jan ^a   Bogdanov, Vladimir Y ^c   Versteeg, Henri H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Outside in signaling; Regulated pre mRNA processing

Indexed keywords

BETA1 INTEGRIN; FULL LENGTH TISSUE FACTOR; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HEMOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TISSUE MICROARRAY; UPREGULATION;

OUTSIDE-IN SIGNALING; REGULATED PRE-MRNA PROCESSING;

ADULT; ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD29; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MIDDLE AGED; THROMBOPLASTIN;

EID: 84879973465     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1307100110     Document Type: Article

References (32)

1. Anczuków O, et al. (2012) The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19(2):220-228.
2. Karni R, et al. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14(3):185-193. (Pubitemid 46355578)
3. Venables JP, et al. (2008) Identification of alternative splicing markers for breast cancer. Cancer Res 68(22):9525-9531.
4. Wang L, et al. (2003) Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 63(15):4724-4730. (Pubitemid 36951053)
5. Courtois S, et al. (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21(44):6722-6728. (Pubitemid 35221914)
6. Okumura N, Yoshida H, Kitagishi Y, Nishimura Y, Matsuda S (2011) Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun 413(3):395-399.
7. Datta D, et al. (2006) Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer. Cancer Res 66(19):9509-9518. (Pubitemid 44623649)
8. Radisky DC, et al. (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436(7047):123-127. (Pubitemid 40966197)
9. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH (2012) The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119(4):924-932.
10. Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W (2004) Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 15(10):4416-4425. (Pubitemid 39299092)
11. Versteeg HH, et al. (2008) Inhibition of tissue factor signaling suppresses tumor growth. Blood 111(1):190-199.
12. Bogdanov VY, et al. (2003) Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat Med 9(4):458-462. (Pubitemid 36460081)
13. Bogdanov VY, et al. (2006) Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 4(1):158-167.
14. Haas SL, et al. (2006) Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 12(30):4843-4849. (Pubitemid 44323209)
15. Hobbs JE, et al. (2007) Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 120(Suppl 2): S13-S21. (Pubitemid 350101769)
16. van den Berg YW, et al. (2009) Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA 106(46):19497-19502.
17. Chandradas S, Deikus G, Tardos JG, Bogdanov VY (2010) Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells. J Leukoc Biol 87(1):147-152.
18. Tardos JG, et al. (2008) SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells. J Thromb Haemost 6(5):877-884. (Pubitemid 351524551)
19. Contrino J, Hair G, Kreutzer DL, Rickles FR (1996) In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2(2):209-215. (Pubitemid 26054985)
20. Rydén L, et al. (2010) Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 126(10):2330-2340.
21. Bluff JE, et al. (2011) Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo. Breast Cancer Res Treat 128(3):691-701.
22. van Nes JG, et al. (2011) COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125(3):671-685.
23. Srinivasan R, et al. (2011) Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling. J Thromb Haemost 9(10):2087-2096.
24. Wang HY, et al. (1998) SRPK2: A differentially expressed SR protein-specific kinase involved in mediating the interaction and localization of pre-mRNA splicing factors in mammalian cells. J Cell Biol 140(4):737-750.
25. Collier ME, Ettelaie C (2010) Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol 30(9):1810-1817.
26. Jessani N, et al. (2004) Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 101(38):13756-13761. (Pubitemid 39298480)
27. Gupta V, et al. (2007) The beta-tail domain (betaTD) regulates physiologic ligand binding to integrin CD11b/CD18. Blood 109(8):3513-3520. (Pubitemid 46572544)
28. Xiong JP, Stehle T, Goodman SL, Arnaout MA (2003) New insights into the structural basis of integrin activation. Blood 102(4):1155-1159. (Pubitemid 36988017)
29. Luque A, et al. (1996) Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem 271(19):11067-11075. (Pubitemid 26155933)
30. Montanez E, et al. (2008) Kindlin-2 controls bidirectional signaling of integrins. Genes Dev 22(10):1325-1330. (Pubitemid 351717522)
31. Martuszewska D, et al. (2009) Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. PLoS ONE 4(2):e4350.
32. Huang CS, Shen CY, Wang HW, Wu PE, Cheng CW (2007) Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. Clin Chim Acta 384(1-2):69-74. Institute